Nuvalent, Inc. (NUVL)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Nuvalent: A Precision Oncology Platform With Two Near-Term Shots On Goal
Nuvalent is positioned as a high-quality late-stage biotech with two near-commercial precision oncology assets, not a traditional value play. NUVL's robust $1.37B cash position and recent $500M raise provide operational runway through 2029, supporting commercialization and expansion without near-term financing risk. Zidesamtinib's NDA for ROS1-positive NSCLC is accepted with a PDUFA date of September 2026; neladalkib NDA submission is planned for 1H 2026, targeting major unmet needs.
Does Nuvalent (NUVL) Have the Potential to Rally 37.26% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 37.3% in Nuvalent (NUVL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Nuvalent, Inc. (NUVL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Nuvalent, Inc. (NUVL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Nuvalent, Inc. (NUVL) Discusses Topline Pivotal Data From ALKOVE-1 Trial of Neladalkib in ALK-Positive Non-Small Cell Lung Cancer Transcript
Nuvalent, Inc. ( NUVL ) Discusses Topline Pivotal Data From ALKOVE-1 Trial of Neladalkib in ALK-Positive Non-Small Cell Lung Cancer November 17, 2025 8:00 AM EST Company Participants Chelcie Lister James Porter - CEO, President & Director Christopher Turner - Chief Medical Officer Alexandra Balcom - CFO & Treasurer Darlene Noci - Chief Development Officer Conference Call Participants Bradley Canino - Guggenheim Securities, LLC, Research Division Marc Frahm - TD Cowen, Research Division Laura Prendergast - Stifel, Nicolaus & Company, Incorporated, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Andrew Berens - Leerink Partners LLC, Research Division Yue-Wen Zhu - LifeSci Capital, LLC, Research Division Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Jin Law - Goldman Sachs Group, Inc., Research Division Kelsey Goodwin - Piper Sandler & Co., Research Division Samuel Alexander Leach - Raymond James & Associates, Inc., Research Division Etzer Darout - Barclays Bank PLC, Research Division Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Colleen Hanley - Robert W.
Nuvalent: Interesting Product, But Aggressive Valuation
NUVL is approaching the precipice of a first targeted therapy approval in lung cancer. They also have an increasingly deep pipeline of therapies, with an audacious phase 3 trial spinning up in ALK-positive NSCLC. Cash position remains strong as well, but the market is pricing in too much success for me to be comfortable at this time.
Nuvalent, Inc. (NUVL) Presents at UBS Virtual Oncology Day Transcript
Nuvalent, Inc. (NASDAQ:NUVL ) UBS Virtual Oncology Day October 1, 2025 3:30 PM EDT Company Participants James Porter - CEO, President & Director Alexandra Balcom - CFO & Treasurer Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Operator Welcome to the UBS Virtual Event. David Dai, you may begin.
Nuvalent: A Logical Acquisition Target
Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC, with impressive Phase I/II trial results and FDA designations. Nuvalent's robust financial position and pipeline make it a prime M&A target, with potential suitors like Pfizer, AstraZeneca, and Novartis. Downside risks include regulatory setbacks, commercialization challenges, strong competition, and financial management, but Nuvalent's cash runway is healthy until 2028.
Nuvalent: Promising Data Keeps Validating Pipeline And Platform
Nuvalent's lead candidates, NVL-520 and NVL-655, show promising efficacy and safety in Phase 1/2 trials. Both drugs have received FDA Breakthrough Therapy and orphan drug designations, with pivotal Phase 2 data expected in 2025 and potential approvals by 2026. The company completed a $500 million secondary offering, reflecting strong investor interest and providing the cash runway through Phase 3.
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
The upside comes after NUVL reported encouraging data on two experimental lung cancer therapies.
Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases
Nuvalent, Inc. achieved positive data from the phase 1/2 ALKOVE-1 study, using NVL-655 for the treatment of patients with ALK-mutant NSCLC. Positive data achieved from phase 1/2 ARROS-1 study, using zidesamtinib for the treatment of patients with ROS-1 mutant NSCLC. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; 3% to 5% are ALK-positive and then 1% to 3% are ROS-1 positive.
Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity
Over the weekend, Nuvalent, Inc. NUVL highlighted the presentation of updated data from Phase 1 dose-escalation portions of the ongoing ARROS-1 Phase 1/2 trial of zidesamtinib and ALKOVE-1 Phase 1/2 trial of NVL-655, at the European Society for Medical Oncology (ESMO) Congress 2024.
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.
